ECSP22076856A - Inhibidores de rip1k - Google Patents
Inhibidores de rip1kInfo
- Publication number
- ECSP22076856A ECSP22076856A ECSENADI202276856A ECDI202276856A ECSP22076856A EC SP22076856 A ECSP22076856 A EC SP22076856A EC SENADI202276856 A ECSENADI202276856 A EC SENADI202276856A EC DI202276856 A ECDI202276856 A EC DI202276856A EC SP22076856 A ECSP22076856 A EC SP22076856A
- Authority
- EC
- Ecuador
- Prior art keywords
- rip1k
- inhibitors
- kinase
- inhibitory compounds
- rip1
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 3
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente descripción se describen compuestos inhibidores de quinasa, tales como los compuestos inhibidores de la proteína quinasa 1 que interactúa con el receptor (RIP1), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas y/o combinaciones descritos pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afección asociada a RIP1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004404P | 2020-04-02 | 2020-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22076856A true ECSP22076856A (es) | 2023-02-28 |
Family
ID=75747027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202276856A ECSP22076856A (es) | 2020-04-02 | 2022-09-30 | Inhibidores de rip1k |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11584758B2 (es) |
| EP (1) | EP4126864A1 (es) |
| JP (2) | JP2023520046A (es) |
| KR (1) | KR20220161433A (es) |
| CN (1) | CN115867548B (es) |
| AR (1) | AR121717A1 (es) |
| AU (1) | AU2021246147B2 (es) |
| BR (1) | BR112022019492A2 (es) |
| CA (1) | CA3173432A1 (es) |
| CL (1) | CL2022002695A1 (es) |
| CO (1) | CO2022014137A2 (es) |
| CR (1) | CR20220492A (es) |
| DO (1) | DOP2022000215A (es) |
| EC (1) | ECSP22076856A (es) |
| IL (1) | IL296916A (es) |
| JO (1) | JOP20220246A1 (es) |
| MX (1) | MX2022012305A (es) |
| PE (1) | PE20230560A1 (es) |
| PH (1) | PH12022552638A1 (es) |
| SA (1) | SA522440778B1 (es) |
| TW (1) | TW202204364A (es) |
| UA (1) | UA128751C2 (es) |
| WO (1) | WO2021203011A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2716136C2 (ru) * | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
| PL3788045T3 (pl) | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| AU2020341708B2 (en) | 2019-09-06 | 2024-01-04 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| ES3043457T3 (en) | 2019-09-06 | 2025-11-25 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| BR112022017099A2 (pt) * | 2020-02-28 | 2022-11-16 | Univ Texas | Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| CN116478150B (zh) * | 2022-01-21 | 2025-09-30 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
| CN116640156B (zh) * | 2022-02-22 | 2025-10-24 | 上海齐鲁制药研究中心有限公司 | Ripk1抑制剂 |
| EP4495119A4 (en) * | 2022-03-16 | 2025-06-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF |
| CN118108633A (zh) * | 2024-01-17 | 2024-05-31 | 浙江工业大学 | 一种l-草铵膦中间体(s)-2-(((苄氧基)羰基)氨基)丁-3-烯酸甲酯的制备方法 |
| WO2025153090A1 (zh) * | 2024-01-19 | 2025-07-24 | 无锡奕拓医药科技有限责任公司 | 一种多并环化合物、其药物组合物及其用途 |
| EP4652998A1 (en) * | 2024-05-21 | 2025-11-26 | Technische Universität München | Treatment of receptor-interacting protein kinase 1- mediated disease with eclitasertib |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2696349A1 (en) | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Heterocyclic inhibitors of necroptosis |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| WO2014145022A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| EP3256467A1 (en) | 2015-02-13 | 2017-12-20 | GlaxoSmithKline Intellectual Property Management Limited | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| WO2017064217A1 (en) | 2015-10-13 | 2017-04-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| WO2017069279A1 (ja) * | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| US9815850B2 (en) * | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3585782A1 (en) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| JP7167069B2 (ja) * | 2017-06-29 | 2022-11-08 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害剤ならびに作製および使用のための方法 |
| EP3781571B1 (en) * | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| PL3788045T3 (pl) * | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
| WO2020001420A1 (zh) | 2018-06-26 | 2020-01-02 | 中国科学院上海有机化学研究所 | 一类细胞坏死抑制剂及其制备方法和用途 |
| CN109134448B (zh) * | 2018-10-16 | 2020-11-27 | 中南大学湘雅医院 | 杂环化合物及其盐、制备方法、用途和药物 |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CA3142360C (en) | 2019-05-31 | 2023-11-14 | Medshine Discovery Inc. | Bicyclic compound as rip-1 kinase inhibitor and application thereof |
| ES3043457T3 (en) | 2019-09-06 | 2025-11-25 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| AU2020341708B2 (en) | 2019-09-06 | 2024-01-04 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| SMT202600151T1 (it) | 2019-11-07 | 2026-05-12 | Rigel Pharmaceuticals Inc | Composti eterociclici inibitori di rip1 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
-
2021
- 2021-03-31 AR ARP210100820A patent/AR121717A1/es unknown
- 2021-04-01 TW TW110112096A patent/TW202204364A/zh unknown
- 2021-04-02 UA UAA202203662A patent/UA128751C2/uk unknown
- 2021-04-02 EP EP21722607.5A patent/EP4126864A1/en active Pending
- 2021-04-02 IL IL296916A patent/IL296916A/en unknown
- 2021-04-02 AU AU2021246147A patent/AU2021246147B2/en active Active
- 2021-04-02 US US17/221,493 patent/US11584758B2/en active Active
- 2021-04-02 CN CN202180038481.3A patent/CN115867548B/zh active Active
- 2021-04-02 KR KR1020227037796A patent/KR20220161433A/ko active Pending
- 2021-04-02 WO PCT/US2021/025598 patent/WO2021203011A1/en not_active Ceased
- 2021-04-02 JP JP2022559872A patent/JP2023520046A/ja active Pending
- 2021-04-02 MX MX2022012305A patent/MX2022012305A/es unknown
- 2021-04-02 BR BR112022019492A patent/BR112022019492A2/pt unknown
- 2021-04-02 PE PE2022002161A patent/PE20230560A1/es unknown
- 2021-04-02 CR CR20220492A patent/CR20220492A/es unknown
- 2021-04-02 PH PH1/2022/552638A patent/PH12022552638A1/en unknown
- 2021-04-02 CA CA3173432A patent/CA3173432A1/en active Pending
-
2022
- 2022-09-30 CL CL2022002695A patent/CL2022002695A1/es unknown
- 2022-09-30 EC ECSENADI202276856A patent/ECSP22076856A/es unknown
- 2022-09-30 DO DO2022000215A patent/DOP2022000215A/es unknown
- 2022-09-30 CO CONC2022/0014137A patent/CO2022014137A2/es unknown
- 2022-10-02 SA SA522440778A patent/SA522440778B1/ar unknown
- 2022-10-04 JO JOP/2022/0246A patent/JOP20220246A1/ar unknown
-
2023
- 2023-01-13 US US18/154,255 patent/US12043629B2/en active Active
-
2024
- 2024-11-08 JP JP2024196081A patent/JP2025032106A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12043629B2 (en) | 2024-07-23 |
| TW202204364A (zh) | 2022-02-01 |
| CN115867548A (zh) | 2023-03-28 |
| CR20220492A (es) | 2023-02-09 |
| BR112022019492A2 (pt) | 2022-11-16 |
| MX2022012305A (es) | 2023-03-06 |
| PH12022552638A1 (en) | 2023-01-16 |
| WO2021203011A1 (en) | 2021-10-07 |
| CL2022002695A1 (es) | 2023-08-11 |
| JP2023520046A (ja) | 2023-05-15 |
| KR20220161433A (ko) | 2022-12-06 |
| CA3173432A1 (en) | 2021-10-07 |
| SA522440778B1 (ar) | 2025-07-08 |
| UA128751C2 (uk) | 2024-10-09 |
| AU2021246147A1 (en) | 2022-10-20 |
| PE20230560A1 (es) | 2023-03-31 |
| CN115867548B (zh) | 2025-03-11 |
| US20210317135A1 (en) | 2021-10-14 |
| DOP2022000215A (es) | 2023-02-28 |
| EP4126864A1 (en) | 2023-02-08 |
| AU2021246147B2 (en) | 2024-01-18 |
| US11584758B2 (en) | 2023-02-21 |
| JP2025032106A (ja) | 2025-03-11 |
| US20230227469A1 (en) | 2023-07-20 |
| IL296916A (en) | 2022-12-01 |
| JOP20220246A1 (ar) | 2023-01-30 |
| CO2022014137A2 (es) | 2023-03-07 |
| AR121717A1 (es) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000215A (es) | Inhibidores de rip1k | |
| DOP2022000051A (es) | Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos | |
| DOP2023000169A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
| CO2023000051A2 (es) | Inhibidores de rip1k | |
| PY2055444A (es) | Composiciones nematicidas | |
| AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
| CO2023012077A2 (es) | Inhibidores heterocíclicos de la cinasa rip1 |